Clinical trials: Glioma Tumor Recurrence
Brain and Central Nervous System Tumors
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating children who have recurrent or…
- Trial name
- NCT00047177
- Testing
- Oxaliplatin
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Pediatric Brain Tumor Consortium
Pediatric Brain Tumor
Compassionate Treatment in Children With Brain Tumors With the Cytotron®
This is a prospective case-control study. This study is expected to last for approximately 12 months, comprised of 4-8 weeks of enrollment period, 28 days of treatment and 6 months of follow up.
- Trial name
- NCT03577600
- Testing
- QMRT with the Cytotron®
- Where
- Mexico
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT)
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor
In this study, we want to find out more about the side effects of an investigational drug for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma, Gallium Maltolate (GaM) and what doses of GaM are safe…
- Conditions
- High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT), Diffuse Midline Glioma, DIPG
- Trial name
- GABRIEL (NCT07331064)
- Testing
- Gallium maltolate
- Volunteers
- 15 people
- Sponsor
- Sarah Rumler
Glioblastoma
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or refractory Glioblastoma
- Trial name
- METT (NCT03243851)
- Testing
- Temozolomide+Metformin
- Where
- 12 sites in South Korea
- Volunteers
- 81 people
- Sponsor
- Yong-Kil Hong
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
ONC201 in Pediatric H3 K27M Gliomas
This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant…
- Trial name
- NCT03416530
- Testing
- Dordaviprone (ONC201)
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Glioblastoma Multiforme
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.
- Trial name
- NCT01268566
- Testing
- MEDI-575
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- MedImmune LLC
Glioblastoma, Astrocytoma
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.
- Trial name
- NCT00335075
- Testing
- Temozolomide, Semustine
- Volunteers
- 151 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent High-grade Glioma, Grade III Astrocytoma
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV…
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- Peds CHAMP1ON (NCT07031765)
- Testing
- exHSC, Nivolumab, Resection or biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Brain Tumor, Recurrent, Vestibular Schwannoma
Vegetative Monitoring During Brainstem-associated Surgery
Intraoperative Monitoring of Heart rate variability, Blood pressure variability, Baroreceptorsensivity etc.
- Conditions
- Brain Tumor, Recurrent, Vestibular Schwannoma, Brainstem Neoplasm, Brainstem Glioma
- Trial name
- NCT03666507
- Testing
- Intraoperative Monitoring during resection of brain tumor
- Where
- Germany
- Volunteers
- 103 people
- Sponsor
- University Hospital Tuebingen
Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma
Multimodality MRI and Liquid Biopsy in GBM
Patients with a new diagnosis of high-grade glioma based on MRI, who are considered surgical candidates determined by neurosurgeons or patients with recurrent glioblastoma with the initial diagnosis of glioblastoma (histologic or…
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Recurrent, Brain Tumor, Primary
- Trial name
- NCT04776980
- Testing
- Post Feraheme Infusion MRI
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ependymoma
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells).
- Trial name
- NCT04903080
- Testing
- HER2 Specific CAR T Cell
- Where
- 13 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
Recurrent Malignant Glioma
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the changes of AE incidence.
- Trial name
- NCT05540873
- Testing
- YYB-103
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CellabMED
Brain Tumor, Anaplastic Astrocytoma
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01095094
- Testing
- ritonavir, lopinavir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
- Trial name
- NCT00006093
- Testing
- cilengitide
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Glioblastoma Multiforme, Glioblastoma
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT04446416
- Testing
- NaviFUS System, Bevacizumab
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Malignant Glioma (WHO Grade III or IV)
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
This is a Phase 1/2 study of the combination of CTO with lomustine in patients with recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
- Trial name
- NCT01989052
- Testing
- CTO, Lomustine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annick Desjardins
Glioma
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in patients with recurrent high grade glioma and in patients with low grade glioma.
- Trial name
- NCT01229644
- Testing
- Crenolanib (CP-868,596)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Glioblastoma, Recurrent Glioblastoma
ASP8374 + Cemiplimab in Recurrent Glioma
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Trial name
- NCT04826393
- Testing
- ASP8374, cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Glioblastoma
BIBF 1120 in Recurrent Glioblastoma Multiforme
VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT01251484
- Testing
- BIBF1120
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Ulrik Lassen